Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Autoimmune diseases cannot currently be cured, only treated, and this is also true for neuromyelitis optica spectrum disorder, which affects the central nervous system. A Kobe University study of how ...

A systematic review identified 15 studies, enabling a meta-analysis of 443 NMOSD patients with 639 pregnancies. Rates of pregnancy-related NMOSD relapses were highest during the first 3 months ...

-- Analyses suggest the B-cell-depleting mechanism of UPLIZNA did not interfere with important immune activity, including COVID-19 infection defenses and antibody levels from childhood vaccines -- ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is currently conducting a clinical study titled An Open-Label ...

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain ...

Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...

The US Food and Drug Administration (FDA) has expanded the indication for the long-acting C5 complement inhibitor, ravulizumab (Ultomiris, Alexion), to include adults with anti–aquaporin-4 (AQP4) ...

"Even mild to moderate pain or depression can have a major negative impact on the patient’s life… pain markedly reduced ability to perform activities of daily living."—Ingo Kleitner, MD, ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April ...